S

Sandoz Group AG
SIX:SDZ

Watchlist Manager
Sandoz Group AG
SIX:SDZ
Watchlist
Price: 37.06 CHF -0.22% Market Closed
Market Cap: 16.3B CHF
Have any thoughts about
Sandoz Group AG?
Write Note

Net Margin
Sandoz Group AG

0.8%
Current
6%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.8%
=
Net Income
77m
/
Revenue
10B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CH
Sandoz Group AG
SIX:SDZ
15.9B CHF
1%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
17%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
19%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
13%
CH
Novartis AG
SIX:NOVN
171.5B CHF
35%
US
Pfizer Inc
NYSE:PFE
151.5B USD
7%
Country CH
Market Cap 15.9B CHF
Net Margin
1%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Sandoz Group AG
Glance View

Market Cap
15.9B CHF
Industry
Pharmaceuticals

Sandoz Group AG, a renowned player in the pharmaceutical industry, stands as a global leader in the production of generic drugs and biosimilars. Originally part of the Swiss corporate giant Novartis, Sandoz has cultivated a reputation for delivering affordable healthcare solutions across the globe. Its foundation lies in the manufacturing of cost-effective, high-quality alternatives to branded medicines, making healthcare more accessible to a broader public. By focusing on generic pharmaceuticals—drugs that are comparable to branded products in terms of dosage, safety, strength, quality, and performance—Sandoz effectively manages to carve out a vital niche in the healthcare ecosystem. This strategic emphasis allows the company to offer a vast portfolio that spans across major therapeutic areas such as cardiovascular, central nervous system, pain management, and oncology, to name a few. Sandoz's business model hinges on its ability to streamline production processes and efficiently navigate regulatory landscapes, which enables the company to sell its products at competitive prices while maintaining profitability. One critical aspect of their operation is the capability to innovate within the generic space, exemplified by their expansion into biosimilars—biopharmaceutical drugs that are highly akin to existing biological products. As patents for major biologics expire, Sandoz capitalizes on the opportunity to introduce biosimilars, thus broadening access to complex therapies. The company invests significantly in research and development to enhance its pipeline of generic drugs and biosimilars, ensuring a steady flow of new market entries. Through a combination of strategic pricing, diverse product offerings, and robust R&D efforts, Sandoz sustains its business model while contributing profoundly to global health, embodying a mission of "Pioneering Access for Patients."

SDZ Intrinsic Value
45.22 CHF
Undervaluation 18%
Intrinsic Value
Price
S

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.8%
=
Net Income
77m
/
Revenue
10B
What is the Net Margin of Sandoz Group AG?

Based on Sandoz Group AG's most recent financial statements, the company has Net Margin of 0.8%.